H.C. Wainwright Thinks Stealth Biotherapeutics’ Stock is Going to Recover

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Stealth Biotherapeutics (MITOResearch Report), with a price target of $1.50. The company’s shares closed last Wednesday at $0.29, close to its 52-week low of $0.16.

According to, Chen has 0 stars on 0-5 stars ranking scale with an average return of -12.7% and a 31.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stealth Biotherapeutics with a $1.25 average price target.

See the top stocks recommended by analysts >>

Stealth Biotherapeutics’ market cap is currently $19.09M and has a P/E ratio of -0.32.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Newton, MA.

Read More on MITO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More